All Oncology News

The IOM makes 10 recommendations for improving care.

The section of General Thoracic Surgery at UC Davis is offering Robotic Thoracic Surgery to further enhance our top regional minimally invasive thoracic surgery program.

The novel PLK1 inhibitor volasertib in combination with low-dose cytarabine has received a Breakthrough Therapy designation from the FDA for its potential as a treatment for patients with untreated AML.

The FDA has approved the first generic formulation of capecitabine, an oral chemotherapeutic that is currently approved to treat patients with metastatic colorectal cancer and metastatic breast cancer.

The FDA has granted Priority Review designation to dabrafenib (Tafinlar) and trametinib (Mekinist) as a combination treatment for patients with unresectable or metastatic melanoma with a BRAFV600E/K mutation.

The monoclonal antibody ofatumumab has received Breakthrough Therapy designation from the FDA that could allow for earlier use in patients with chronic lymphocytic leukemia.

The FDA's Oncologic Drugs Advisory Committee voted 13-0 with one abstention in support of pertuzumab in combination with trastuzumab and docetaxel for patients with HER2-positive breast cancer in the neoadjuvant setting.

Found to be helpful for patients with head and neck cancer.

A phase III trial examining the anti-CTLA-4 immune checkpoint inhibitor ipilimumab in men with metastatic castration-resistant prostate cancer failed to meet its primary endpoint of prolongation in overall survival.

The novel HDAC inhibitor entinostat in combination with exemestane has received a Breakthrough Therapy designation from the FDA for its potential to reverse resistance to hormonal therapies used to treat patients with advanced ER-positive breast cancer.

The hope for many targeted therapies is that they will eventually be used in patients with earlier stage disease; for the breast cancer drug pertuzumab (Perjeta), that hope is being put to the test.

The FDA has approved nab-paclitaxel plus gemcitabine as a first-line treatment for patients with metastatic adenocarcinoma of the pancreas, an area of high unmet need with few effective treatments.

The investigational MAGE-A3 immunotherapeutic did not significantly extend disease-free survival (DFS) in certain patients with postsurgical melanoma when compared with a placebo in a phase III study.

The first patient has been enrolled in a phase III clinical program investigating treatment with olaparib for patients with BRCA-mutated ovarian cancer, marking another step in the revived development of an agent once relegated to the sidelines.

UC Davis CLSP is a multidisciplinary program for comprehensive lung cancer screening.

The FDA has given priority review designation to sorafenib for the treatment of locally advanced or metastatic RAI-refractory differentiated thyroid cancer.

Healthcare providers have until September 23, 2013 to comply.

A two-pronged approach that includes carbohydrate antigen 125 (CA-125) testing proved highly accurate in screening women for ovarian cancer, including aggressive forms of the disease.

Brought to you by the UC Davis Section of General Thoracic Surgery: PulmaCalc PPO is a predicted post-operative pulmonary function calculator

Patients with advanced renal cell carcinoma could experience a greater quality of life and the same treatment benefit with pazopanib as opposed to sunitinib.

Adding ruxolitinib to capecitabine significantly improved the survival rate of a subgroup of patients with recurrent or treatment-refractory pancreatic cancer compared with patients in the same population who received capecitabine alone.

The use of a chemoresponse assay to assess therapy choices for patients with recurrent ovarian cancer correlated with dramatic improvements in overall survival and progression-free survival.

PACES trial will evaluate 2 drugs to prevent colon adenomas.

Nearly two decades after clinical trials began, the investigational immunotherapy Allovectin failed to meet key endpoints in a phase III trial in patients with stage III/IV metastatic melanoma and will no longer be developed.

A phase III trial exploring necitumumab plus chemotherapy as a first-line therapy for patients with metastatic squamous non-small cell lung cancer has demonstrated an improvement in overall survival when compared to chemotherapy alone.

Employers bear a large number of costs.

Patients with mutations of BRCA1 or BRCA2 who received tamoxifen after their initial diagnosis of breast cancer reduced their chances of developing contralateral or secondary breast cancer by more than half.

Gifts to healthcare providers, including lunches, are now required to be tracked and reported.

The aim of these courses is to improve the care of patients aged 15-39.

OncLive today announced the 2013 "Giants of Cancer Care," 12 luminaries selected by oncology industry peers for their remarkable achievements in research and/or clinical practice.